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Abstract
Alpha-fetoprotein (AFP) is a tumor marker
routinely used for the diagnosis and follow-up of
malignant neoplasms. We report a case of
extremely high serum levels of AFP associated
with benign lesions of the liver and of the lungs
with a spontaneous and gradual drop to normal
values in the 9-month follow-up without any
form of treatment. As a result a high serum level
of AFP does not necessarily indicate a malig-
nant tumor and every patient presenting with
such finding must be thoroughly examined
before making a definitive diagnosis.  
Introduction
Alpha-fetoprotein (AFP) is a major plasma
protein physiologically produced by the yolk
sac and the liver during fetal development. The
normal AFP serum level in adult men and non-
pregnant women should be under 10 ug/L. An
increase in AFP level is associated with active
regeneration of hepatocytes, as in the pres-
ence of a tumor.1 AFP-secreting tumors include
hepatocellular carcinoma (HCC) and other
mainly gastrointestinal or gem cell malignant
neoplasms. In patients affected by these
tumors, serum levels of AFP often correlate
with tumor size and surgical resection or
effective chemotherapy is usually associated
with its drop. AFP is therefore a useful marker
to help making the correct diagnosis as well as
assessing response to treatment.
The association between AFP and benign
tumors is very rare and only a few cases have
been described in the literature. We present a
patient with focal nodular hyperplasia (FNH)
of the liver and nonspecific reactive pulmonary
nodules whose AFP serum level at presentation
exceeded 6000 times the normal value. The
exaggerated AFP-value spontaneously and
gradually dropped to normal values in the 9-
month follow-up. 
Case Report
An 82-year-old male patient was referred by
his general practitioner to the Department of
Hematology and Oncology of Schwerin Medical
Center, a tertiary hospital in northern
Germany, due to unexplained weight loss of
about 4 kg over the previous 3 months as well
as abnormal findings on a routine chest x-ray. 
The patient had a history of excessive alco-
hol consumption and smoking until about 20
years before, apart from that no history of any
chronic disease. No association with any occu-
pational pathogen and no exposure to
Mycobacterium tuberculosis could be identi-
fied. The physical examination did not reveal
any significant abnormality, apart from a ten-
der and slightly enlarged liver of about 3 cm
under the costal arch. Laboratory investiga-
tions revealed a mild normochromic normocyt-
ic anemia (7.8 mmol/L, normal range 8.6-12.0)
and a mild increase of bilirubin (29 umol/L,
normal range <17). All other routine parame-
ters and liver function tests were normal.
Serologically there were no sign of present or
past hepatitis or HIV infection. The
Quantiferon-Gold™ test was negative. Among
all tested tumor markers the only significant
increase was registered for Alpha-fetoprotein
at 60.187 ug/L (normal <10) and therefore a
malignant tumor was suspected.
In order to secure the diagnosis we per-
formed a computed tomography (CT) scan of
chest, neck and abdomen. Here a big lesion of
the right liver lobe measuring about 10×9.5 cm
with signs of early stage liver damage as well
as multiple bilateral pulmonary nodules of
maximum 8×6×5 mm was described. Both pul-
monary and liver structures underwent a CT-
guided biopsy. Histologically there was no evi-
dence of malignant cells, fibrosis or inflamma-
tion in the biopsy material from the lung, while
the biopsy material from the liver revealed
FNH (Figure 1). Abdominal magnetic reso-
nance imaging, gastroscopy, colonoscopy and
bronchoscopy with broncho-alveolar lavage,
did not add any relevant information (Figure
2). In absence of malignancy, the clinically sta-
ble patient was diagnosed with FNH of the liver
as well as nonspecific reactive pulmonary nod-
ules and was released from our hospital with-
out any treatment, being offered a short time
follow-up. On discharge (day 15) a first sub-
stantial AFP drop was registered (now at
13.371 ug/L, a 77%-decrease compared to the
previous value).
The first follow-up was performed after two
weeks (day 30) and a CT scan was repeated.
The patient was feeling good and had normal
appetite. At this time the lung nodules
appeared to be decreased both in quantity and
in size and the FNH of the liver also appeared
smaller in size, now at about 6.5×6.5 cm.
Moreover AFP had remarkably decreased at
5.293 ug/L (60% decrease compared to the pre-
vious value). 
In the second follow-up (day 60) a further
decrease in size of both liver and lung nodules
(now almost disappeared) was described. AFP
was now at 3.632 ug/L (a further decrease of
about 22%) and our asymptomatic patient was
gaining weight (Figure 3). 
We performed other three follow-ups at day
90, 120 and 270, where a further decrease of
AFP was described (83.6, 94.4 and 90.9% drop
compared the previous value respectively). At
day 270 (9 months after first presentation)
AFP was normal (3 ug/L) and radiological
abnormalities had completely disappeared.
Discussion and Conclusions
The reported case describes a rare associa-
tion between very high levels of AFP and non-
malignant lesions of liver and lungs.
Reviewing the literature we only found a paper
that reported elevated levels of AFP in a patient
with FNH.2 The value described was at around
114 ug/L much lower than the one we report.
Furthermore a spontaneous drop in AFP levels
without any form of treatment has not been
described yet. We conclude that highly
increased serum levels of AFP do not always
indicate the presence of HCC or other malig-
nancies, but may be found also in non-malig-
nant liver lesions such as FNH. AFP serum lev-
els should therefore be re-checked at regular
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intervals, as a spontaneous drop may be possi-
ble even in absence of therapy. 
An association between FNH and nonspecif-
ic reactive lung nodules may be possible.
Further studies are needed to prove this asso-
ciation. 
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                             Case Report
Figure 1. Multiple bilateral lung nodules
on computed tomography scan at presen-
tation. Histology excluded the presence of
malignant cells.
Figure 2. Focal nodular hyperplasia of the
liver on magnetic resonance imaging at
presentation. Figure 3. Spontaneous regression of lung
nodules on second follow-up (day 60). No
therapy had been performed. 
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